Baxter to build a vaccine plant in the Czech Republic

U.S. medical products group Baxter International said on Monday that it would build a 176-million USD vaccine manufacturing plant in Austria, as well as a smaller facility in the Czech Republic. Baxter described the project as state-of-the-art manufacturing facilities using cell culture and recombinant technology. Gordon Busenbark, head of Baxter's Austrian operations, said the Czech plant will employ around 200 scientific and technical staff. He declined to give precise details about the cost of the Czech investment, he added though that the information would be released in the near future.